Detalhe da pesquisa
1.
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Oncologist
; 22(3): 245-254, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28220020
2.
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Oncologist
; 21(4): 402-3, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26984445
3.
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.
Blood
; 123(25): 3887-94, 2014 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-24802775
4.
Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
J Hepatol
; 61(6): 1253-9, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25048952
5.
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
J Thorac Oncol
; 12(2): 383-389, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27464970
6.
A phase 1 study of anti-TGFß receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 79(4): 673-680, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28280971
7.
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 77(6): 1253-62, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27139036
8.
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.
Clin Cancer Res
; 22(2): 301-9, 2016 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26324738
9.
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
Clin Cancer Res
; 22(21): 5204-5210, 2016 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27797971
10.
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.
J Clin Oncol
; 34(13): 1500-9, 2016 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26926681